nice to hear your still in wal still a lot of reasons to stay in here imho we will be rewarded just would like it to be soon rather than later so i could move some money elsewhere . and will take a look at VOG cheers keep the faith juggler
I'm still in, comical at times here, you can understand why the very long termers get frustrated, I still stand by the fundimentals and will hold for some time to come, Off topic, have a look at VOG, got in there a while back and am showing a small loss, but taps due to be turned on very soon, could be an early Chrizy present, as always DYO ah fek it you know the score. Love this board, helpful and polite, as always, keep up the good work. GL, as always. WAL.
We are currently where we are just on MS results and potential alone, once favorable results are shown from present P3 trials for pain relief, mobility etc for cancer patients, then it opens up a whole new potential market. With the protection of license in place and world market awaiting, who knows where this could end up. Impo, bright future, GL
Effective european protection just ahead of phase three trial results. In response to a few earlier this is phase 3: Phase III Phase III studies are randomized controlled multicenter trials on large patient groups (300–3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for chronic medical conditions. It is common practice that certain Phase III trials will continue while the regulatory submission is pending at the appropriate regulatory agency. This allows patients to continue to receive possibly lifesaving drugs until the drug can be obtained by purchase. Other reasons for performing trials at this stage include attempts by the sponsor at "label expansion" (to show the drug works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing), to obtain additional safety data, or to support marketing claims for the drug. Studies in this phase are by some companies categorised as "Phase IIIB studies." While not required in all cases, it is typically expected that there be at least two successful Phase III trials, demonstrating a drug's safety and efficacy, in order to obtain approval from the appropriate regulatory agencies such as FDA (USA), or the EMA (European Union), for example. Once a drug has proved satisfactory after Phase III trials, the trial results are usually combined into a large document containing a comprehensive description of the methods and results of human and animal studies, manufacturing procedures, formulation details, and shelf life. This collection of information makes up the "regulatory submission" that is provided for review to the appropriate regulatory authorities in different countries. They will review the submission, and, it is hoped, give the sponsor approval to market the drug. Most drugs undergoing Phase III clinical trials can be marketed under FDA norms with proper recommendations and guidelines, but in case of any adverse effects being reported anywhere, the drugs need to be recalled immediately from the market. While most pharmaceutical companies refrain from this practice, it is not abnormal to see many drugs undergoing Phase III clinical trials in the market. I think theyve had US phase 3 and now waiting Uk results. Maybe world patent up next, then results then lets fly. Phase IV is post market response. Down at present but ever hopeful and optomistic with this share. Once the true potential is understood then this could change lives. Gl
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.